Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

NAD

This article was originally published in The Tan Sheet

Executive Summary

Novartis has halted use of claim that Rx Transderm Scop patch is "clinically proven more effective than Dramamine," CBBB division says in recent Case Report. Pharmacia brought the issue to NAD's attention, which recommended Novartis remove superiority claims from ads and provide a drowsiness disclaimer (1"The Tan Sheet" Nov. 13, 2000, p. 11). Following Novartis' unsuccessful appeal to NARB, NAD concludes firm has "made a good faith effort to comply" with advertising division's recommendations "in both its print advertising and redesigned Web site"...
Advertisement

Related Content

Topics

Advertisement
UsernamePublicRestriction

Register

PS093235

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel